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The NF1 somatic mutational landscape in
sporadic human cancers
Charlotte Philpott, Hannah Tovell, Ian M. Frayling, David N. Cooper and Meena Upadhyaya*
Abstract
Background: Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an
autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1
gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known function of the
NF1 gene product neurofibromin is to downregulate RAS. NF1 exhibits variable clinical expression and is
characterized by benign cutaneous lesions including neurofibromas and café-au-lait macules, as well as a
predisposition to various types of malignancy, such as breast cancer and leukaemia. However, acquired somatic
mutations in NF1 are also found in a wide variety of malignant neoplasms that are not associated with NF1.
Main body: Capitalizing upon the availability of next-generation sequencing data from cancer genomes and
exomes, we review current knowledge of somatic NF1 mutations in a wide variety of tumours occurring at a
number of different sites: breast, colorectum, urothelium, lung, ovary, skin, brain and neuroendocrine tissues, as well
as leukaemias, in an attempt to understand their broader role and significance, and with a view ultimately to
exploiting this in a diagnostic and therapeutic context.
Conclusion: As neurofibromin activity is a key to regulating the RAS/MAPK pathway, NF1 mutations are important in
the acquisition of drug resistance, to BRAF, EGFR inhibitors, tamoxifen and retinoic acid in melanoma, lung and breast
cancers and neuroblastoma. Other curiosities are observed, such as a high rate of somatic NF1 mutation in cutaneous
melanoma, lung cancer, ovarian carcinoma and glioblastoma which are not usually associated with neurofibromatosis
type 1. Somatic NF1 mutations may be critical drivers in multiple cancers. The mutational landscape of somatic NF1
mutations should provide novel insights into our understanding of the pathophysiology of cancer. The identification of
high frequency of somatic NF1 mutations in sporadic tumours indicates that neurofibromin is likely to play a critical
role in development, far beyond that evident in the tumour predisposition syndrome NF1.
Keywords: NF1, Sporadic tumours, Somatic mutations, Cancer, Melanoma, Lung cancers, Glioblastoma, Leukaemia,
Breast cancer, Phaeochromocytoma
Background
Neurofibromatosis type 1 (NF1: Online Mendelian In-
heritance in Man (OMIM) #162200) is an autosomal
dominantly inherited tumour predisposition syndrome.
Affecting 1/3000–4000 individuals worldwide, it results
from constitutional mutations of the NF1 gene, lo\cated
on the long arm of human chromosome 17 [1–4]. A var-
iety of characteristic clinical features are associated with
NF1, including hyperpigmentary abnormalities of the
skin (café-au-lait macules (CALMs) and inguinal/axillary
freckling, iris hamartomas (Lisch nodules) and the
growth of benign peripheral nerve sheath tumours
(neurofibromas) in the skin. Neurofibromas can be di-
vided into several different subtypes and are associated
with a variety of clinical complications. Cutaneous
neurofibromas are small, discrete dermal tumours ob-
served in most, but not all, adult NF1 patients [5]. The
generally much larger plexiform neurofibromas (PNFs),
a more diffuse tumour type, are present in 30–50% of
NF1 patients. Importantly, some 10–15% of these benign
PNFs subsequently develop into aggressive malignant per-
ipheral nerve sheath tumours (MPNSTs) which are the
main cause of morbidity in NF1 [6–8]. A number of other
tumours are also associated with NF1, including optic gli-
omas, juvenile myelomonocytic leukaemia (JMML), benign
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or malignant phaeochromocytomas, gastrointestinal stro-
mal tumours, glomus tumours, juvenile xanthogranulomas,
rhabdomyosarcomas and lipomas.
NF1 is a tumour suppressor gene; in order for a par-
ticular cell to become cancerous, both alleles of a
tumour suppressor gene must be mutated. This concept,
known as the ‘two-hit’ hypothesis, was first proposed by
Knudson, and the majority of NF1-associated tumours
exhibit biallelic inactivation of NF1 [9, 10].
The NF1 gene is spread over a large locus (350 kbp) at
17q11.2. It contains 61 exons, including four alterna-
tively spliced exons, and is transcribed into a 12 kbp
messenger RNA (mRNA) containing an open reading
frame of 8454 nucleotides [11]. Curiously, intron 27b,
the largest intron of NF1 at 61 kbp, contains three em-
bedded genes, OMGP, EVI2B and EVI2A, that are all
transcribed in the opposite orientation to NF1 but whose
protein products appear to have little or no interaction
with neurofibromin [11].
Neurofibromin: the NF1 gene product
Neurofibromin is a 2818 amino acid, multidomain pro-
tein. Although ubiquitously expressed, its highest levels
are to be found in cells of the central nervous system
(CNS), where it is often found in association with tu-
bulin. Neurofibromin is a member of a large family of
evolutionarily conserved proteins: the mammalian Ras-
GTPase-activating protein (GAP)-related proteins, and
its most highly conserved region is the centrally located
GAP-related domain (GRD), which is encoded by exons
20–27a. The best understood function of neurofibromin
is its role in tightly regulating cellular levels of activated
RAS proteins. All RAS proteins exist in two cellular
states, the majority being found in their inactive GDP-
bound form, with only a very small fraction present in
their metabolically active GTP-bound form. Only in
their GTP-bound form are RAS proteins able to upregu-
late the many downstream effector proteins that form
part of the RAS/RAF/MAPK signalling pathway [12–16].
The key role of neurofibromin is to downregulate the ac-
tivated GTP-bound RAS by stimulating the low intrinsic
GTPase activity of the RAS proteins themselves, thereby
promoting the conversion of active RAS-GTP into its in-
active RAS-GDP state. Hence, any loss of neurofibromin
functionality, due to inactivating mutations in NF1, will
result in sustained intracellular levels of active RAS-
GTP, resulting in prolonged activation of the RAS/RAF/
MAPK signalling pathway and ultimately a loss of
growth control and increased cellular proliferation.
Increased active RAS-GTP levels also stimulate the
PI3K/AKT/mTOR signalling pathway which protects
cells from apoptosis. In the absence of functional neuro-
fibromin, the pathway can become constitutively acti-
vated resulting in an increase in cell proliferation and
survival. The RAF/MAPK and PI3K/AKT pathways both
activate mTOR signalling, a process found to be highly
regulated in neurofibromas whereby mTOR pathway ac-
tivation occurs in the absence of growth factors, in both
NF1 tumours and neurofibromin-deficient cultured cells.
Indeed, the mTOR pathway is constitutively activated in
neurofibromin-deficient primary cells and tumours, and
is regulated by phosphorylation and inactivation of the
TSC2-encoded protein tuberin by AKT, ERK and RSK
[13, 17]. It has also been suggested that increased RAS
activity in brain cells may be associated with NF1-
related learning deficiencies; it may result in long-term
impairment as a result of increased GABA-mediated in-
hibition [18]. Neurofibromin levels and therefore Ras
signalling can also be affected by mechanisms other than
NF1 mutation including ubiquitination [19].
Neurofibromin is known to associate with a large number
of proteins, including tubulin, kinesin, protein kinases A
and C, syndecan, caveolin, cytokeratin intermediate fila-
ments and the amyloid precursor protein, although the bio-
logical significance of these protein-protein interactions is
largely unknown. The diversity of protein associations
does however emphasize the point that neurofibromin
is likely to have many functions other than merely func-
tioning as a GAP protein [14, 20]. Nonetheless, to date,
only the function of the GAP-related domain of neuro-
fibromin is fully understood, so it is to be hoped that
new molecular studies will reveal additional functional
properties of neurofibromin [21].
Mutation analysis of the NF1 gene
The germline mutation rate of NF1 is some 10-fold
higher than that observed for most other inherited dis-
ease genes, with more than half of NF1 cases attributed
to de novo mutations [7]. Currently, over 2600 different
inherited mutations in NF1 have been reported in the
Human Gene Mutation Database (HGMD®) as a cause
of NF1, varying in size from large genomic deletions
spanning several megabases to single base-pair substitu-
tions that alter an encoded amino acid or the function of
a splice site [22–26]. There is, however, no evidence of
any localized mutation clustering within NF1. Whilst the
constitutional NF1 mutational spectrum is well defined
with missense/nonsense (27.7%), splicing (16.3%), micro-
deletions (26.9%), microinsertions (11.1%), indels (2.0%),
gross deletions (>20 bp; 13.3%), gross insertions (>20 bp;
2.0%), complex rearrangements (0.6%) and a couple of
putative regulatory mutations, there is no evidence of
any localized mutation clustering within NF1 [27, 28].
The majority (>80%) of constitutional NF1 mutations
are inactivating, predicted to result in almost complete
absence of the transcript or protein [25]. Approximately
5–10% of all heritable NF1 mutations involve gross
DNA alterations, mainly genomic deletions spanning the
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whole gene and flanking region, as well as intragenic
multi-exon rearrangements [29]. Constitutional muta-
tions have not been identified in any of the four alterna-
tively spliced exons in research studies, but this may be
due to ascertainment bias, as the majority of clinical la-
boratories that analyse NF1 do not screen these alterna-
tive exons for mutations.
A subset of the many NF1 splicing mutations, i.e. deep
intronic mutations, result in the creation of novel ac-
ceptor/donor splice sites. These may give rise to the in-
clusion of a novel cryptic exon into the transcribed
mRNA, leading to the production of an aberrant neuro-
fibromin protein. Such mutations account for ~2% of all
reported constitutional NF1 mutations [30].
To date, only three NF1 families with gonadal or germ-
line mosaicism have been reported [31–33]. In such fam-
ilies, only a small proportion of the germ cells, whether
sperm or ova, will carry the new NF1 mutation, but this
can nevertheless result in more than one affected child be-
ing produced by clinically normal parents [34].
A major challenge for clinicians and geneticists deal-
ing with NF1 is the successful identification and
characterization of causative NF1 mutations in their pa-
tients. This problem relates to a number of features of
the NF1, including its large genomic size (~350 kbp)
and complexity (61 exons), the absence of any obvious
mutational hotspots or recurrent mutations, and the
wide spectrum of mutation types observed. Indeed, the
lack of mutational clustering and the paucity of recur-
rent mutations necessitates analysis of the entire NF1
gene in the search for potential pathogenic mutations.
Furthermore, given the broad spectrum of known NF1
mutations, no single mutation detection test can, as
yet, successfully identify all such mutation types [35].
Furthermore, some 30% of all NF1 mutations are pre-
dicted to cause aberrant splicing, and for this reason,
the analysis of both RNA and DNA from patients in
mutation screening protocols is clearly required [25].
Whilst the majority of NF1 splicing mutations occur
within consensus acceptor and donor splice site se-
quences, a number of missense, nonsense, and even ‘si-
lent’ mutations may also result in aberrant splicing,
which are often only identifiable by screening a pa-
tient’s RNA [25]. As well as the challenges in collection
and analysis of patient mRNA, a frequent issue is the
difficulty in interpreting the clinical diagnostic signifi-
cance of putative NF1 missense mutations, as this may
require a family segregation study and/or in vitro func-
tional analysis to determine the pathogenicity (or other-
wise) of the variant in question [25, 36].
Furthermore, many highly homologous NF1 pseudo-
gene sequences are scattered throughout the human
genome and can often interfere with PCR-based diag-
nostic tests. This emphasizes the need for the careful
selection of PCR primers to avoid non-specific amplifi-
cation of these pseudogene sequences.
The spatial distribution of NF1 microdeletions is
strongly influenced by the presence of a number of low-
copy repeats (LCRs) spanning the 17q11.2 region that
encompasses the NF1 gene. Indeed, studies into NF1
microdeletions have provided a general model to under-
stand the different mutational mechanisms underlying
large genomic rearrangements associated with inherited
diseases [37].
The NF1 mutation detection rate in classical NF1 pa-
tients can be up to 95%. However, somatic mutation de-
tection is more challenging, largely because of the
cellular heterogeneity which is characteristic of tumour
tissue [38]. Mutations in multiple genes encoding the
components of the RAS/MAPK pathway predispose pa-
tients to develop clinical features that overlap with those
of NF1, e.g. Legius syndrome, Noonan syndrome inter
alia, and the majority of these conditions are associated
with tumours [39].
Tumour biology
All cancers originate from a single cell that starts to behave
abnormally due to acquired somatic mutations in its gen-
ome. These somatic mutations may be the consequence of
impaired DNA replication machinery, exogenous or en-
dogenous mutagen exposures, enzymatic modification of
DNA or defective DNA repair.
A subset of these somatic changes, termed ‘driver mu-
tations’, confer a selective growth advantage and are im-
plicated in cancer development, whereas the remainder
are considered to be ‘passengers’ [40]. The Cancer Gen-
ome Atlas (TCGA), International Cancer Genome Con-
sortium (ICGC), Catalogue of Somatic Mutations in
Cancer (COSMIC) and cBioPortal for Cancer Genomics
collectively represent the results of large-scale sequen-
cing of cancers, thereby capturing many of the genomic
alterations driving malignancy [41–44]. The cBio Cancer
Genomics Portal is an open-access resource for the
interactive exploration of multidimensional cancer gen-
omics data sets, currently providing access to data from
more than 5000 tumour samples from 147 cancer
studies [44–46]. It contains data on somatic NF1 muta-
tions in different types of tumour including melanoma
(desmoplastic, skin cutaneous and uveal), breast carcin-
oma, neuroendocrine prostate cancer, glioblastoma, lung
adenocarcinoma and squamous cell carcinoma, urothe-
lial carcinoma, uterine carcinoma, adenoid and ovarian
serous cystadenocarcinoma, paraganglioma, phaeochro-
mocytoma, pancreatic cancer, adrenocortical carcinoma,
stomach adenocarcinoma, sarcoma, oesophageal cancer,
rhabdomyosarcoma and many more. In this review, we
detail the frequency of somatic NF1 mutations in many
non-NF1-associated sporadic cancers including melanoma,
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glioblastoma, neuroblastoma, breast cancer, ovarian serous
carcinoma, paraganglioma and phaeochromocytoma, lung
adenocarcinoma, lung squamous cell carcinoma, bladder,
colorectal and leukaemia. Further, it is anticipated that with
the advent of powerful sequencing technologies, combined
with precise microdissection of tissue, somatic NF1 muta-
tions will be identified in additional tumour types. Somatic
NF1 mutations are important not only because they may be
drivers but also because they may contribute to resistance
to therapy [47]. Elucidation of the mutational landscape of
somatic NF1 mutations in a large number of sporadic tu-
mours, their role in the initiation and progression of tu-
mours and how they can confer resistance or sensitivity to
a therapeutic intervention may provide further insight into
the mechanisms underlying tumour development and ul-
timately aid the development and targeting of therapies.
The frequency of somatic NF1 mutations in different
sporadic tumour types derived from the literature is
given in Table 1. The cBioPortal for Cancer Genomics
provides a web resource for exploring, visualizing and
analysing multidimensional cancer genomics data and
provides graphical summaries of gene-level data from
multiple platforms, shown in Fig. 1 [45].
Main body
Melanoma
Melanoma is a skin cancer that arises from melanocytes.
Although the precise causes of melanomas are still not fully
understood, environmental exposure to ultraviolet (UV) ra-
diation from sunlight or tanning lamps certainly increases
the risk of developing melanoma. Although NF1 is associ-
ated with pigmentary abnormalities such as CALMs, malig-
nant melanoma is not a tumour type associated with NF1.
Somatic mutation analysis of melanoma by next-
generation sequencing has been performed at multiple
centres leading to the identification of several different
pathways thought to be involved in the initiation and
progression of melanoma.
The direct involvement of NF1 in melanoma was first
reported by Andersen and colleagues in 1993 who iden-
tified a homozygous NF1 deletion in one of eight malig-
nant melanoma cell lines which resulted in the loss of
detectable NF1 mRNA and neurofibromin protein [48].
Furthermore, the apparent absence of neurofibromin
and NF1 mRNA was recorded in a primary melanoma.
This led to their proposal that NF1 may function as a
tumour suppressor gene in the development or progres-
sion of malignant melanoma. Many subsequent studies
have identified additional somatic NF1 mutations in
melanoma in 12–30% of cases [45, 49–55].
RAS/MAPK pathway dysregulation has been identified
as a key culprit in non-familial melanoma, leading to the
discovery of BRAF and NRAS as the most commonly
mutated genes [56]. Indeed, BRAF mutations occur in
50–70% of all cutaneous malignant melanomas, whilst
NRAS alterations only occur in 19–28% of tumours. In
both cases, these gene lesions result in constitutive acti-
vation of the MAPK pathway and are believed to be
early somatic events associated with melanoma initiation
[56, 57]. The high frequency of BRAF and NRAS muta-
tions in melanomas has recently been confirmed by
high-throughput next-generation sequencing (NGS) ana-
lysis which also identified additional driver mutations,
including a recurrent RAC mutation, which is the third
most frequent activating mutation in sun-exposed mela-
nomas after BRAF and NRAS mutations [50, 51].
Inactivating NF1 mutations have been detected in ap-
proximately 13% of melanomas, alongside mutations in
other tumour suppressor genes, including TP53, ARID2,
PTEN, CDKN2A, MAP2K1 and RB1 [51]. The impact on
NRAS is however non-uniform, with some NF1 mutant
melanomas exhibiting full NRAS activation (i.e. the same
activation level as oncogenic NRAS mutations), whereas
others exhibit only partial activation [51]. In a mouse
melanoma model, NF1 mutations cooperate with BRAF
mutations in the pathogenesis of melanoma by prevent-
ing oncogene-induced senescence, an indication that
NF1 plays a key role in early melanoma development
[58]. In both mouse tumour models and A375 human
melanoma cell lines, Maertens and colleagues have
shown that resistance to treatment was enhanced by fur-
ther suppression of NF1 by small hairpin RNA (shRNA).
Furthermore, they observed that resistance to the BRAF
inhibitor PLX4720 was attenuated by reconstitution of
Table 1 Frequency of somatic NF1 mutations in different
human neoplasms
Neoplasm Frequency of somatic
NF1 mutations
References
Cutaneous melanoma 12–30% [49–51, 58]
Desmoplastic melanoma 45–90% [60, 61]
Lung adenocarcinoma 7–11.8% [65–67, 166,
176, 177]
Lung squamous cell carcinoma 10.3–11% [72, 177]
Acute myeloid leukaemia 3.5–23.6% [82–85]
T cell acute lymphoblastic
leukaemia
3% [88]
Breast cancer 2.5–27.7% [106, 177]
Ovarian carcinoma 12–34.4% [113, 115, 170,
177–180]
Paraganglioma/
phaeochromocytoma
21–26% [121, 124, 177]
Neuroblastoma 2.2–6% [130]
Glioblastoma 14–23% [132, 134, 177]
Colon adenocarcinoma 3.8–6.25% [143, 177]
Bladder transitional cell
carcinoma
6–14% [149, 167, 177]
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Fig. 1 (See legend on next page.)
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NF1 in these cells [58]. Using RNA interference (RNAi)
screening techniques, Whittaker and colleagues confirmed
that NF1 mutation is a key mechanism in BRAF inhibitor
resistance. An RNAi screen, targeting more than 16,500
genes in a BRAF inhibitor-sensitive melanoma cell line,
identified NF1 as the highest ranking protein affected by
BRAF inhibition, and that, NF1 knockdown abrogated the
growth inhibitory effects of BRAF inhibition [53]. Indeed,
it was found that NF1 suppression led to a 31-fold
increase in resistance to PLX4720, as well as a partial
(7-fold) resistance to MEK inhibition, demonstrating
that human melanoma samples with innate resistance
to BRAF inhibition and sensitivity to a MEK inhibitor
harboured NF1 mutations [53].
Importantly, NF1 mutations have been found in mela-
nomas that lack both BRAF and NRAS mutations, with
25–30% of such melanomas found to harbour deleteri-
ous NF1 mutations, thus implying that NF1 inactivation
has conferred aberrant MAPK pathway activation in
these tumours [50, 51]. BRAF/NRAS wild-type and NF1
mutant melanomas are strongly associated with UV
damage, as evidenced clinically by the higher degree of
solar elastosis and, at a molecular level, by a high pro-
portion of C > T transitions at pyrimidine dimers and
more frequent tandem CC>TT transitions [59].
A recent study based on 213 human melanoma sam-
ples identified three frequently mutated genes: BRAF,
NRAS and NF1, with frequencies of 38.5, 28.6 and
12.2%, respectively [49]. Whilst known recurrent activat-
ing mutations were identified in BRAF and NRAS, a high
number of inactivating mutations were identified in
NF1. Notably, almost half (26/56) of BRAF and NRAS
wild-type melanomas had an NF1 mutation, most identi-
fied by loss of heterozygosity (LOH). Furthermore, NF1
mutation-containing melanomas also harboured signifi-
cantly more somatic mutations across all loci and oc-
curred in significantly older patients, although they were
associated with similar overall patient survival rates as
compared to BRAF or RAS mutant or BRAF-RAS-NF1
wild-type melanoma. In addition, all 26 NF1 mutant
BRAF-RAS wild-type melanomas carried mutations in
other known RASopathy genes, including RASA2,
PTPN11, SOS1, RAF1 and SPRED1 [49]. In contrast to
Whittaker and colleagues, Krauthammer et al. also
found that 6/10 NF1 mutant cell lines were highly sensi-
tive to a MEK inhibitor, whereas the other four were
highly resistant, clearly indicating that NF1 suppression
is not always associated with either sensitivity or resist-
ance to MEK inhibitor [49, 53].
Desmoplastic melanoma
The highest frequency of somatic NF1 mutations were
found in desmoplastic melanomas (14/15) [60]. These
melanomas are characterized by their higher propensity
for local recurrence and less frequent metastatic spread to
regional lymph nodes. The high frequency of NF1 muta-
tions in desmoplastic melanomas appears to indicate an
important role for neurofibromin in the specific biology of
this type of melanoma. Another recent study screened 20
desmoplastic melanomas by exome sequencing for alter-
ations in the MAPK and PI3K signalling pathways, i.e.
mutations in CBL, ERBB2, MAP2K1, MAP3K1, BRAF,
EGFR, PTPN11, MET, RAC1, SOS2, NRAS and PIK3C,
which were found in 15/20 (75%), with NF1 mutations be-
ing found in 9/20 (45%) [61].
Uveal melanoma
Melanoma of the uveal tract (i.e. iris, ciliary body and chor-
oid) is rarer than cutaneous melanoma but is nevertheless
the most common primary intraocular malignancy in
adults, with inactivating mutations found in approximately
60% (23/38) of uveal melanomas [62]. Intriguingly, whilst
not malignant, the Lisch nodules characteristic of NF1 is
hamartomatous uveal melanocytic proliferations of the iris.
Mucosal melanoma
Mucosal melanoma differs from cutaneous melanoma in
terms of its molecular profile, with less frequent BRAF
and more frequent KIT mutations but also has a poor
prognosis. In a recent study [63] of a cohort of 75 tu-
mours from patients with a mucosal melanoma, NF1
and RAS mutations were identified in 18.3 and 16.9%
samples, respectively, whereas 8.4 and 7% of tumour
samples harboured BRAF and KIT mutations [63]. This
study demonstrates that NF1 is the most frequently oc-
curring driver mutation in mucosal melanoma.
(See figure on previous page.)
Fig. 1 The frequency and nature of somatic NF1 mutations in different cancer types derived from the cBio dataset. a Malignant melanoma. b Lung
adenocarcinoma. c Lung squamous cell carcinoma. d Small cell lung carcinoma. e Acute lymphocytic leukaemia (ALL). Acute myeloid leukaemia (AML),
chronic lymphocytic leukaemia (CLL), malignant myeloma (MM) and myelodysplastic syndrome (MDS). f Breast carcinoma. g Serous ovarian carcinoma.
h Brain glioma, including glioblastoma multiforme (GBM). i Colorectal carcinoma. j Bladder transitional cell carcinoma. Mutations = single base-pair
substitutions, in-frame microdeletions/insertions, frameshift microdeletions/insertions, splice site mutations (including those that can create in-frame
deletions via exon skipping), nonsense mutations and frameshift insertions/deletions (shown in green); deletions = gross, multi-exonic and whole gene
deletion identified as copy number changes (shown in blue); amplification = multi-exonic, whole gene duplications identified as copy number changes
(shown in red); multiple alterations = some combination of mutations, deletions and/or amplification (shown in grey) [44–46]
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Lung cancer
Lung cancer is responsible for about 10% of all cancer
cases worldwide; the vast majority of which has been at-
tributed to tobacco smoking [64]. The two main types
are non-small cell lung cancer (NSCLC) in 80–90%
cases and small cell lung cancer (SCLC) found in 10–
15% of patients. NSCLC has multiple subtypes, including
adenocarcinoma (ADC), squamous cell carcinoma
(SqCC) and undifferentiated (large cell) lung carcinoma.
Adenocarcinoma
Approximately 40% of NSCLC are ADC, and several
studies have reported somatic NF1 mutations in some
7–11% of ADC [65–68]. The high mortality rate charac-
teristic of this tumour type is due in part to the frequent
presentation of such tumours at a locally advanced or
metastatic stage and the lack of an effective advanced
stage treatment [65, 69]. A number of potential novel
therapeutic targets have been identified, including the
activating mutations in KRAS, BRAF, ERBB2 and
PIK3CA; the translocations in RET and ROS1; and the
loss of function or deletions of TP53, NF1, CDKN2A
and KEAP1 [65, 70]. Whilst NF1 mutations were only
found in 7% (13/188) of sporadic lung ADC [65], further
analysis found that biallelic inactivation at the NF1 locus
may be present in as many as 23% (3/13), although it is
not known whether these lesions occurred in cis or in
trans [65]. Similarly, Imielinski et al. identified somatic
NF1 mutations in 10.9% (20/183) of lung ADC, of which
half were found to be truncating mutations, resulting in
a complete loss of function [66].
In addition to NF1 being recurrently mutated in a sub-
set of sporadic lung ADC patients, the MAPK pathway
also appears to be an important regulatory pathway in-
volved in tumorigenesis [65]. The TCGA research net-
work examined the genomes, RNA and some protein
from 230 previously untreated lung ADC and matched
normal samples [41, 67]. In three quarters of the sam-
ples, the group identified mutations in NF1 and other
genes that activate the RTK/RAS/RAF cell signalling
pathway. This study not only identified loss-of-function
NF1 defects but also demonstrated that NF1 mutations
(as well as KEAP1 and TP53 mutations) are far more
frequent in the BRAF-RAS oncogene-negative subset of
lung ADC. Additionally, TCGA and other groups have
identified genes such as TP53, KRAS, STK11 (LKB1),
EGFR and NF1 to be significantly mutated in ADC [67].
Markedly reduced NF1 mRNA expression in ADC has
been found to confer both an intrinsic and an acquired
resistance to EGFR inhibitors [71]. By performing a
genome-wide siRNA screen of both a human lung cancer
cell line and a murine mutant EGFR-driven lung ADC,
this revealed reduced NF1 mRNA expression in both, and
furthermore, whilst the EGFR inhibitor erlotinib failed to
fully inhibit RAS-ERK signalling when neurofibromin
levels were reduced, treatment of neurofibromin-deficient
lung cancers with MEK inhibitor restored sensitivity to
erlotinib [71].
In a recent study of 591 NSCLC, 60 had NF1 muta-
tions (10%) whilst 141 (24%) harboured KRAS mutations
[68]. Approximately 25% of the NF1 mutations co-
occurred with mutations in known oncogenes: BRAF,
ERBB2, KRAS, HRAS and NRAS. Therapeutic strategies
targeting KRAS activation, including the use of inhibitors
of MAP kinase signalling, may warrant investigation in
NF1 mutant tumours. Additional tumour suppressor in-
activation pattern studies may help to inform novel
treatment strategies.
Squamous cell carcinoma
According to the TCGA, somatic NF1 changes are
present in approximately 12% of squamous cell lung
cancers (SqCC), of which four distinct subtypes have
been identified: classical, primitive, basal and secretory
expression [72]. The basal expression subtype was found
to harbour NF1 alterations, suggesting a potential direc-
tion for the treatment of such tumours. The information
from the TCGA studies has highlighted the involvement
of NF1 in both lung ADC and SqCC and served to im-
prove our understanding of the genetic pathways that
lead to lung cancer [72].
Transcriptome analysis of 153 tumour samples, in-
cluding ADC, SqCC, large cell lung cancer, adenoid
cystic carcinomas and derived cell lines, has been in-
tegrated with the data from The Cancer Genome
Atlas and other published sources [73]. This confirms
the previously reported CD74-NRG1 fusion and also
suggests that the NRG1, NF1 and Hippo pathway fu-
sions may play important roles in tumours without
known driver mutations and that this prognostic fac-
tor may be associated with poor survival [73]. Several
different gene fusions, viz. NF1-GOSR1, NF1-PSMD11,
NF1-NLK, NF1-DRG2 and NF1-MYO15A, were also
detected by transcriptome sequencing of lung cancers
[73]. Interestingly, both lung ADC and SqCC DNA
displayed a significantly increased frequency of guan-
ine (cytosine) to thymine (adenine) mutations, a type
of mutation associated with exposure to tobacco
smoke [68]. Lung ADC genomes also manifest re-
gional heterogeneity in terms of the distribution of
mutations with sequencing data from lung cancer
studies clearly indicating that lung cancer, at the mo-
lecular level, is a highly heterogeneous disease. In-
deed, the mutational landscape of lung ADC is
substantially different from that of SqCC of the lung
or SCLC [74], with frequent receptor tyrosine kinase
mutations found in lung ADC, that are rarely en-
countered in either SqCC or SCLC [75].
Philpott et al. Human Genomics  (2017) 11:13 Page 7 of 19
Mutations in TP53, KRAS, LKB1, NF1 and RBM10 are
enriched in transversion-high tumours, whilst mutations
in EGFR, RB1 and PIK3CA and in-frame insertions in the
receptor tyrosine kinases EGFR and ERBB2 are enriched
in transversion-low tumours [75]. The transversion-high
group was found to be strongly associated with past or
present smoking (P < 2.2 × 10−16) [72, 74, 75].
To compare lung ADC and SqCC and to identify new
drivers of lung carcinogenesis, Campbell and colleagues
examined the exome sequences and copy number pro-
files of 660 lung ADC and 484 lung SqCC tumour nor-
mal pairs [74]. They observed median somatic mutation
rates of 8.7 mutations/Mbp and 9.7 mutations/Mbp for
lung ADC and SqCC, respectively. At least 38 genes
were significantly mutated in lung ADC and 20 genes in
SqCC; however, only six genes, TP53, RB1, ARIDIA,
CDKN2A, PIK3CA and NF1, were significantly mutated
in both tumour types, and of these, TP53, CDKN2A and
PIK3CA mutations had a significantly higher frequency
in lung SqCC. Recurrent alterations in lung SqCC were
more similar to those of other squamous carcinomas
than to alterations in lung ADCs, whilst the significantly
mutated genes in lung ADC were most similar to those
associated with glioblastoma and colorectal cancer.
Small cell lung cancer
Although there is a paucity of data for small cell lung
cancer (SCLC), the frequency of NF1 mutations in SCLC
was found to be 2.4 and 6.9% in two independent studies
[76, 77]. In a subsequent study of 98 SCLC, DNA was
sequenced to a high, uniform coverage and analysed for
all classes of genomic alterations [78]. Of the seven most
commonly altered genes identified, only one (RICTOR)
was considered to be actionable in terms of treatment.
The most common non-actionable genomic alterations
were found in TP53 (86% of SCLC cases), RB1 (54%)
and MLL2 (17%), with NF1 mutations identified in only
3% of SCLC, consistent with the earlier studies.
Myeloid malignancies
Myeloid malignancies are clonal disorders characterized
by acquired somatic mutations in various haematopoietic
progenitors. Constitutional NF1 mutations are known to
predispose individuals to myeloid malignancies such as
chronic myelomonocytic leukaemia (CMML), JMML and
acute myeloid leukaemia (AML) [79]. Somatic 17q11 dele-
tions encompassing NF1 have been described in many
adult myeloid malignancies [80]. More generally, the RAS
signalling pathway has been found to be fundamental in
the development of myeloid malignancies, with somatic
activating mutations in NRAS and KRAS genes estimated
to be present in 20 to 40% of diagnosed cases of AML,
CMML and JMML [81]. Recent advances in understand-
ing the genetic basis of myeloid malignancies have
provided important insights into the pathogenesis of
AML. Whilst somatic KRAS and NRAS mutations are fre-
quently found in AML, mutations in other RAS signalling
pathway genes, including NF1, occur at lower frequencies,
although the reported frequency for NF1 somatic muta-
tions ranges quite widely from 3.5 to 23.6% [79, 82–85].
Parkin and colleagues identified NF1 mutations in 7%
of cases with AML, with a further 12% displaying copy
number alterations (CNAs) involving NF1, mainly het-
erozygous deletions [85]. The absence of NF1 expression
was observed in 7% of adult AML associated with an in-
creased RAS-GTP level. In another study of AML with
CBHB-MYHII rearrangements, 16% of the samples har-
boured NF1 deletions [84]. However, high-resolution
studies have failed to provide any evidence for frequent
NF1 alterations in de novo AML, although they sug-
gested that NF1 mutations may contribute to tumour
progression [82]. In this study, the authors screened a
total of 488 previously untreated de novo AML patients
for the NF1 deletion using either array comparative
genomic hybridization (aCGH) or real-time quantitative
PCR/fluorescence in situ hybridization approaches.
Using aCGH, a small ~0.3 Mbp minimally deleted region
involving NF1 was defined; the overall frequency of NF1
deletion was 3.5% (17/485). Furthermore, NF1 deletion
was significantly associated with abnormal cytogenetics
and a monosomal karyotype, whilst only one of five
NF1-deleted patients acquired a coding mutation in the
remaining allele. This study indicates that NF1 microle-
sions are infrequent in de novo AML and may be sec-
ondary events in leukemic progression.
Myelodysplastic syndrome
The frequency of NF1 changes in myelodysplastic
syndrome has been found to vary between 0 and 9%
[86, 87].
T cell acute lymphoblastic leukaemia
T cell acute lymphoblastic leukaemia (T-ALL) is a vari-
ant of acute lymphoblastic leukaemia (ALL), with fea-
tures similar to some types of lymphoma. It accounts for
about 15 and 25% of ALL in paediatric and adult co-
horts, respectively.
T-ALL is a highly aggressive malignancy, characterized
by rapid progression and high relapse rates [79]. Somatic
mutations in a number of established T-ALL drivers
such as KRAS, NRAS, PIK3CA, PTEN, NOTCH1, PHF6
and NF1 have been identified in T-ALL cell lines and pa-
tient samples [88]. Somatic NF1 mutations have been
found in 27.3% (9/33) of the T-ALL cohort; however,
only 12.1% (4/33) were non-synonymous mutations [88].
The type 1 NF1 microdeletion (1.4 Mb) was reported in
2.9% (3/103) of T-ALL patients [79]. None of these three
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individuals with the microdeletion exhibited any clinical
characteristics of NF1.
Juvenile myelomonocytic leukaemia
JMML is a myeloproliferative neoplasm (MPN) of child-
hood, occurring when too many immature white blood
cells (myelocytes and monocytes) are made in the bone
marrow. In 1997, Side and colleagues reported constitu-
tional NF1 mutations in 15% of JMML patients [89].
JMML generally carries a very poor prognosis, with the
only curative treatment being haematopoietic stem cell
transplantation.
JMML was once considered a unique example of
RAS-driven oncogenesis because it was thought to be
initiated by mutually exclusive mutations in the RAS
genes (NRAS or KRAS) or in several RAS pathway regu-
lators (PTPN11, NF1 or CBL) [90].
In an exploration of the somatic mutation landscape of
30 patients with syndromic (n = 8) or sporadic (n = 22)
JMML, a combination of genome-wide DNA array analysis,
whole-exome sequencing and targeted sequencing was
used in paired germline and tumour samples [90]. In total,
85 somatically acquired genetic alterations were found in
83% (25/30) of patients in this sub-cohort. Genes contain-
ing somatic variants detected by whole-exome sequencing,
or previously reported to be mutated in JMML, were then
sequenced in the full cohort of 118 JMML cases. A total of
122 secondary clonal abnormalities, in addition to initiating
RAS pathway mutations, were identified in 49% (58/118) of
patients [90]. In addition, sequencing of isolated myeloid
colonies demonstrated the coexistence of multiple RAS hits
in the same myeloid progenitors in three of the JMML
cases tested, challenging the concept of mutually exclusive
RAS pathway mutations.
The polycomb recessive complex 2 (PRC2) is involved
in cellular differentiation, maintenance of cell identity
and proliferation as well as stem cell plasticity [91] and
also drives myeloid malignancies. Nf1/Kras double-
mutant mice have been shown to develop myeloid ma-
lignancies with reduced latency and increased severity in
comparison to mice with only one of the two defects be-
cause copy number variations (CNVs) in Nf1/Kras mu-
tant mice frequently resulted in haploinsufficiency for
PRC2 core subunits (SUZ12 or EZH2) or PRC2-
associated factors necessary for optimal PRC2 activity
(AEBP2, CDYL or JARID2) [92]. In addition, haploinsuf-
ficiency for multiple genes that regulate PRC2 function
can cooperate in myeloid transformation, and other mu-
tations in JMML target a small number of pathways spe-
cifically, including components of the RAS and PRC2
networks [93, 94]. Thus, RAS activation is a major
player, and other pathways such as PRC2 are also im-
portant. Notably, PRC2 also plays a role in the develop-
ment of MPNSTs. Loss of function of PRC2 (due to
mutations in EED or SUZ12) is also found in the vast
majority of sporadic, NF1-associated, and radiotherapy-
associated MPNSTs (where PRC2 loss amplifies Ras-
driven transcription) [95, 96].
In a recent study focussing on characterization of ser-
ial samples from JMML patients at diagnosis and then
beyond through relapse and transformation to AML,
mutations were found in NF1, NRAS, KRAS, PTPN11 or
CBL in 85% of patients, as well as recurrent mutations
in other genes involved in signal transduction, splicing,
PRC2 and transcription. The number of somatic alter-
ations present at diagnosis appeared to be important for
the outcome of JMML [97].
Breast cancer
The NF1 gene is reported to be frequently mutated in
sporadic breast cancers, although in only a few studies
has mutation frequency been published. NF1 patients
have an increased risk of developing breast cancer as
compared to the general population [8, 98]. In particular,
women under the age of 50 with NF1 have an increased
(4–5-fold) risk of developing breast cancer (standardized
incidence ratio for women under 50) and also a 3.5-fold
increased fatality risk (proportionate mortality ratio)
[98–100]. A predisposition to breast cancer in NF1 pa-
tients has led researchers to postulate the potential in-
volvement of somatic NF1 mutations in initiating and
driving the malignant transformation and progression of
sporadic breast cancer. A number of breast cancer gen-
ome sequencing studies have identified NF1 as one of a
number of novel, recurrently mutated genes in sporadic
tumours which could potentially be targeted in a thera-
peutic context [101, 102].
It was Ogata and colleagues, working with established
breast cancer cell lines in 2001, who first identified a
role for NF1 in the malignant transformation of mam-
mary cells [103]. Further analysis of the NF1 deletion-
bearing tumours revealed significantly higher levels of
active RAS, indicating that RAS signal transduction
pathway dysregulation, through NF1 loss, may be re-
sponsible for driving malignancy in these cells. Neurofi-
bromin was found to be below detectable levels in the
highly malignant and treatment-resistant MB-231 breast
cancer cell line as compared with four other less aggres-
sive cell lines. Additionally, the MB-231 cells exhibited a
10-fold increase in pMAPK levels as a result of activated
Ras, despite there being no changes in p120GAP. Hence,
this study suggested that under-expression of NF1 and
reduced neurofibromin activity may have a direct influ-
ence on malignant transformation and resistance to
anti-cancer agents [103]. This is consistent with other
studies and goes some way towards accounting for the
presence of the somatic NF1 mutations found in spor-
adic breast tumours.
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The mouse model Chaos3 is characterized by the
spontaneous development of mammary tumours, due to
a mutation in Mcm4 leading to chromosomal instability
through disruption of the MCM2-7 complex [104, 105].
Somatic NF1 deletions were found in almost all (59/60)
of the mammary tumours studied in this mouse model,
and upon subsequent examination of TCGA data, it was
noted that NF1 is somatically mutated or deleted in
27.7% of human breast cancers [105, 106].
Large-scale NGS to compare primary and recurrent
breast cancer has found mutations in recurrent tumours
which were not present in matched primary tissue [107].
However, the difficulties inherent in studying recurrent
tumours mean that the sample size was necessarily small
in this study, with only 74 matched tumours from 43 pa-
tients across the various breast cancer subtypes. So, the
precise role for NF1 in breast cancer is still unclear and
further studies are required.
CNAs dominate the breast cancer genome, with NF1
gene amplification being a particular feature not seen in
the other tumour types in which NF1 mutations are ob-
served (Fig. 1), suggesting that gain of neurofibromin
function is especially important in breast cancer biology.
In contrast, genes generally mutated in breast cancers
are subject to a low frequency of somatic mutations, in-
cluding single nucleotide mutations and indels in driver
genes [105, 106].
Large-scale efforts by the TCGA and ICGC have con-
tributed greatly towards determining the identity of
genes mutated in breast cancer, but analysis of clinical
associations in these data sets is limited by the scarcity
of long-term patient follow-up data and the stringent
criteria used for sample selection (e.g. tumour size, ma-
lignant cellularity) [41, 42].
In a recent study based on 2433 molecular profiles of
breast cancer, it was noted that high levels of intra-
tumour heterogeneity was generally associated with a
worse clinical outcome, with one exception: highly ag-
gressive breast tumours with 11q13–14 amplification
had low levels of intra-tumour heterogeneity [108, 109].
Inactivating NF1 mutations were also found to be associ-
ated with breast cancer severity score in oestrogen
receptor-negative tumours.
As with melanoma and neuroblastoma, inactivation of
NF1 in breast cancer is associated with resistance to
drug therapy. A potential mechanism for NF1 and drug
resistance in breast adenocarcinoma has been suggested
following analysis of the MCF-7 breast cancer cell line
[110]. Silencing of NF1, amongst several other genes,
has been shown to confer a tamoxifen-resistant pheno-
type, although it was noted that resistance- or
sensitivity-specific gene expression patterns may give a
better prediction of treatment outcome as compared to
single genes [111]. This is potentially of great clinical
importance, of course, as, although tamoxifen is one of
the most widely used anti-breast cancer agents, it is now
apparent that up to ~40% of early-stage breast cancer
patients who receive tamoxifen as an adjuvant therapy
will ultimately develop tamoxifen resistance and relapse
[111, 112].
Ovarian cancer
High-grade serous ovarian carcinoma (HGOSC) is the most
common and malignant form of ovarian tumours account-
ing for up to 70% of all ovarian cancer cases. Some serous
cancers may initiate in cells at the distal end of the fallopian
tube, then spread to the ovary. There are different subtypes
of epithelial ovarian cancer including mucinous, endome-
trioid, clear cell, undifferentiated or unclassifiable; therefore,
HGOSC is a molecularly and clinically heterogeneous dis-
ease which accounts for the majority of ovarian cancer
deaths.
More than a third of all ovarian serous carcinomas
(OSCs) harbour somatic NF1 mutations, identifying an
alternative target for treatment and an additional prog-
nostic marker. This is of particular importance when
considering the disease heterogeneity, high relapse and
fatality rates [113, 114].
A role for NF1 in ovarian serous carcinoma (OSC) was
first proposed by Sangha et al. in 2008 [113]. Genome-
wide microarray analysis of 36 primary OSC identified
homozygous NF1 deletions in two tumours. This group
subsequently screened 18 ovarian carcinoma-derived cell
lines and 41 primary OSC for additional NF1 alterations,
with 8/18 cell lines exhibiting marked reduction or no
expression of NF1. Homozygous NF1 gene deletions and
NF1 splicing mutations were identified in 9/41 primary
OSC. Additionally, tumours and cell lines with NF1 le-
sions were found to lack KRAS and BRAF mutations,
whilst exhibiting Ras pathway activation [113].
The Cancer Genome Atlas project analysed the ex-
pression of mRNA and microRNA, promoter methyla-
tion and DNA copy number in 489 HGOSC and
performed genomic DNA analysis in 316 tumours. Loss
of NF1 function was identified in 12% (37/316) of sam-
ples, and of these, 24 had deletions, one had a duplica-
tion and the remaining (12) samples harboured other
somatic mutations. The Australian Ovarian Cancer
Study (AOCS) specifically examined CNAs and reported
regions of copy number loss at the NF1 locus in 34%
(137/398) of ovarian cancer samples, comprising 157
serous adenocarcinomas from the TCGA cohort and a
further 241 samples, of both endometrioid and serous
subtypes [115].
HGOSC shows a simple mutational profile, with TP53
nearly always mutated, but with other genes, including
NF1, mutated at a low frequency [116]. Approximately
50% of all HGSOCs exhibit homologous recombination
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(HR) deficiency, with such tumours being highly sensi-
tive to PARP inhibitors [117]. However, NF1 mutations
identified in advanced HGOSC are associated with re-
sistance to treatment because of the acquisition of differ-
ent new mutations within the gene [116–118].
Paragangliomas and phaeochromocytomas
Phaeochromocytomas are rare tumours (annual incidence
of 1–6 million per year) that develop from neural crest-
derived chromaffin cells and produce excess catechol-
amine, resulting in hypertension and flushing. Despite be-
ing rare in the general population, the frequency of
occurrence amongst NF1 patients is much higher, with
0.1–6% developing a phaeochromocytoma [119, 120].
NF1 is one of a number of known paraganglioma and
phaeochromocytoma susceptibility genes, constitutional
mutations in which are responsible for inherited tumour
syndromes. Somatic NF1 mutations occurred in 35/161
(21.7%) of sporadic phaeochromocytomas, with the ma-
jority exhibiting LOH and low NF1 mRNA expression
[121–123], whilst somatic mutations in the susceptibility
genes NF1, MAX, RET, VHL, SDHA, SDHB, SDHC,
SDHD, SDHAF2, KIF1Bβ and TMEM127 are present in
11–19% of sporadic cases [124–126]. It has also been
demonstrated that the majority (83%, 35/42) of sporadic
phaeochromocytomas harbour a CNA in at least one of
these susceptibility genes, thereby altering respective
protein expression levels [123]. This is in addition to the
26% (11/42) of sporadic paragangliomas and phaeochro-
mocytomas that have lost one NF1 allele, associated with
a reduction in NF1 mRNA level. Furthermore, 10 of 11
tumours were also observed to harbour a somatic
protein-truncating NF1 mutation in the second allele
[121]. This study also identified a correlation between
NF1 mutations and a biochemical phenotype: paragan-
gliomas and phaeochromocytomas harbouring a somatic
NF1 mutation were found to display higher plasma
levels of normetanephrine (P = 0.005) and metanephrine
(P = 0.0025), markers for catecholamine-secreting tu-
mours [121]. This could be of significance as plasma cat-
echolamine levels are used in the diagnosis of
phaeochromocytoma and paraganglioma; however, these
findings were reported in only a small sample group and
the biochemical data was non-centralized and incom-
plete, limiting their overall significance [123].
A large-scale analysis of a cohort of 202 paraganglio-
mas and phaeochromocytomas, collected by the Cortico
et Médullosurrénale: les Tumeurs Endocrines (COMETE)
network, examined CNAs, somatic and constitutional
mutations in known susceptibility genes [124]. Almost a
quarter (25/119) of the sporadic phaeochromocytomas/
paragangliomas carried an inactivating NF1 mutation, of
which 21/25 were associated with the loss of the wild-
type allele. Of all the somatic mutations identified in the
study, 56% were located in NF1, showing that NF1 is fre-
quently mutated in phaeochromocytomas/paraganglio-
mas [124].
Neuroblastoma
Neuroblastoma is a neuroendocrine tumour that origi-
nates from neural crest cells of the sympathetic nervous
system, with most tumours developing in the abdomen.
Neuroblastoma is the second most common solid tumour
in childhood and accounts for 8% of all childhood cancers.
The treatment for neuroblastoma includes surgery,
chemotherapy, radiation and bone marrow transplant-
ation. Familial neuroblastoma cases comprise only a small
fraction (~1–2%) of all neuroblastoma cases, and their
genetic aetiology is relatively well understood [127, 128].
In contrast, far less is known of the genetic aetiology of
sporadic neuroblastomas, despite their accounting for the
majority of cases.
It was a quarter of a century ago when NF1 was first re-
ported to play a role in the development of neuroblastoma.
In this study, 4/10 neuroblastoma cell lines were observed
to express either a reduced level or a complete absence of
neurofibromin, with NF1 mutations being identified in two
of these cell lines [129]. Furthermore, it was demonstrated
that the introduction of a normal human chromosome 17
into a neuroblastoma cell line suppressed its tumorigen-
icity. Several NF1-deficient neuroblastoma cell lines exhib-
ited only moderately elevated Ras−GTP levels, in contrast
to NF1 tumour cells, indicating that neurofibromin can
contribute differently to the negative regulation of RAS in
different cell types [130, 131].
Somatic NF1 mutations in neuroblastomas have been
correlated with reduced expression of neurofibromin
and poor patient prognosis, whilst higher levels of ex-
pression are associated with longer progression-free sur-
vival [130, 131]. Hölzel and colleagues also reported a
loss of neurofibromin expression in 8/25 neuroblastoma
cell lines and that a further SNP analysis of 20 neuro-
blastoma cell lines detected 50% (10/20) with abnormal
NF1 alleles [130]. Genomic aberrations in NF1 were also
found in primary neuroblastomas but at a lower fre-
quency of 6% (5/83).
A large-scale RNAi screen revealed an association of
NF1 loss in neuroblastoma cell lines with resistance to
retinoic acid (RA) treatment which is used as targeted
therapy in the treatment of neuroblastomas. Loss of NF1
activates RAS-MEK signalling, which in turn represses
ZNF423, a critical transcriptional coactivator of the ret-
inoic acid receptors; neuroblastomas with low levels of
both NF1 and ZNF423 have an extremely poor outcome.
However, inhibition of MEK signalling downstream of
NF1 restores responsiveness to RA, suggesting a poten-
tial therapeutic strategy to overcome RA resistance in
NF1-deficient neuroblastomas [130].
Philpott et al. Human Genomics  (2017) 11:13 Page 11 of 19
Glioblastoma
Glioblastomas are tumours that arise from astrocytes that
comprise the supportive tissue of the brain. These tu-
mours are usually aggressive as the cells divide rapidly and
are also supported by a large network of blood vessels.
The most aggressive subtype is glioblastoma multiforme
(GBM) which is the most frequent form of brain cancer in
adults, renowned for its lethality and poor prognosis and
is thus an important target of study [132, 133].
Glioblastoma-associated NF1 somatic mutations are
well described [132, 134, 135], with recurrent driver mu-
tations being identified in NF1 and a number of other
candidate genes (IDH1, TP53, CDK4, EGFR, PI3KR1,
PIK3CA, PTEN, RB1 and CDNK2A) in GBM [132]. NF1
mutations were identified in at least 15% (16/105) of all
GBM by Parsons and colleagues, although chromosomal
translocations or epigenetic changes were not tested in
this cohort [132].
A TCGA analysis assessed levels of gene expression,
CNAs and DNA methylation in a cohort of 206 glio-
blastoma tumour samples, with recurrent mutations in
NF1, AKT3, PRK3R1 and PARK2 being identified, and
with 14% (13/91) of samples found to contain at least
one somatic NF1 mutation. Verhaak and colleagues sub-
sequently performed large-scale genomic analysis of
these TCGA data, dividing glioblastoma cases into four
subtypes: proneural, neural, classical and mesenchymal
[136]. They found that GBM with NF1 and PTEN alter-
ations had a distinct mesenchymal-like expression pro-
file, with 53% of mesenchymal cases having an NF1
mutation. The mutual exclusivity of NF1 and BRAF mu-
tations in GBM has also been reported [134].
In animal models, inactivation of TP53 and PTEN may
cooperate with NF1 loss in the development of glioblastoma
[137]. Haploinsufficiency of NF1 is also reported to increase
astrocyte proliferation and enhancement of angiogenesis in
Nf1+/− heterozygous mouse models [138, 139].
Colorectal cancer
Colorectal cancer (CRC) is one of the leading causes of
cancer-related deaths in the western world, with at least
50% of CRCs exhibiting dysregulation of the RAS/
MAPK pathway. Reports of the type of NF1 mutations
in CRC vary widely, with NF1 LOH first reported in 14–
57%, and reported gains in part of, or even a complete
duplication of, the NF1 gene in 17% of CRC [140–142].
The 2012 TCGA genome-scale analysis of 212 CRC
found that 24 genes were predominantly mutated, in-
cluding NF1 in approximately 5.6% (11/212) of cases
[143]. Subsequent studies have confirmed this, with NF1
mutations being identified in 5.6% (4/72) and 5.8% of
cases (39/619), respectively [144, 145].
Several critical genes and pathways, such as WNT,
RAS/MAPK, PI3K, TGF-β, P53 and DNA mismatch
repair, are recognized in the initiation and progression
of CRC [146, 147]. Although genetic alterations in the
PI3K and RAS/MAPK pathways are common in CRC
and NF1 alterations have been detected in 5–6% of
cases, it remains unclear as to whether NF1 mutations
in CRC are related to chemotherapeutic effect.
Urinary tract transitional cell carcinoma
The best documented molecular factors involved in
urothelial transitional cell carcinoma (TCC) are the RAS
proto-oncogene activation and TP53 mutations. Alter-
ations in NF1 gene expression in TCC were first reported
in 1999 [148], where decreased NF1 gene expression was
observed in 83% (23/29) of TCC specimens (as estimated
by immunohistochemistry), whilst NF1 mRNA levels were
markedly lower in TCC tissue as compared with those in
adjacent non-neoplastic urothelium. Neurofibromin levels
were also decreased in high-grade TCC, suggesting that al-
terations of NF1 gene expression might be involved in
urinary TCC carcinogenesis. Whole genomic analysis per-
formed on 35 stage IV urothelial cancers that had relapsed
and progressed after primary surgery and conventional
chemotherapy revealed NF1 mutations in two cases (6%)
[149]. Integrated analysis of 131 urothelial carcinomas
showed recurrent mutations in 32 genes, with 14% of tu-
mours having NF1 mutations.
Other malignant tumours
There are a number of other malignant tumour types that
have been found to harbour NF1 alterations including
neuroendocrine prostate cancer (24%), myxofibrosarco-
mas (10.5%) and pleomorphic liposarcomas (8%), pancre-
atic cancer (11%), gastric adenocarcinoma (10%) and
rhabdomyosarcoma (7%) [44, 45]. Somatic NF1 mutations
have also been detected in 41–72% of sporadic MPNSTs,
showing that NF1 inactivation plays a major role in the
development of this tumour type [96].
General discussion
Neurofibromatosis type 1, caused by constitutional inacti-
vating mutations in the tumour suppressor gene NF1, is a
neurodegenerative disorder predisposing individuals to
both benign and malignant tumours [150–152]. Addition-
ally, somatic mutations of NF1 are also frequent in desmo-
plastic, cutaneous and mucosal melanoma, high-grade
serous ovarian cancer, breast cancer, phaeochromocyto-
mas and paragangliomas, glioblastoma multiforme, mye-
loid malignancies, neuroblastoma, and colorectal and
urinary bladder transitional cell carcinoma (Table 1). Ab-
errations in neurofibromin result in the dysregulation of
the RAS/MAPK pathway leading to unregulated cell
growth and proliferation. The related mTOR pathway and
other downstream activators and effectors of RAS includ-
ing PI3K are also involved in cancer [17, 153].
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Mutations (chromosomal aberrations, nucleotide sub-
stitutions and epigenetic aberrations) in a subset of can-
didate genes are likely to confer a growth advantage
resulting in the development of cancer. Cancer encom-
passes more than 100 different diseases, the study of
which provides insight into both the commonalities and
differences between and amongst various types and sub-
types of cancer [147]. In order to understand this com-
plex disease and to develop novel targeted therapeutics,
it is essential to characterize the somatic mutational
spectra in each cancer genome in order to facilitate our
understanding of the biological processes underlying the
cancer as well as the pathways of evolutionary prog-
ression. The availability of the human genome reference
sequence enabled the rapid resequencing of cancer ge-
nomes, leading to the discovery of many additional can-
cer genes, revealing for the first time the molecular
heterogeneity of cancer genomes and identifying thera-
peutic targets. To improve the diagnosis and treatment
of cancer patients, several large-scale cancer genomics
projects, e.g. the TCGA, ICGC, cBioPortal and COS-
MIC, have been undertaken in recent years [41–44].
These pan-cancer projects have generated high-
throughput data which provide valuable opportunities to
understand the biology, initiation and progression of hu-
man cancers. One caveat, however, is distinguishing
artefactual DNA damage from the bona fide mutations
that actually occurred in the tumour, given that it has
been reported that mutagenic damage accounts for the
majority of the erroneous identification of variants with
low to moderate (1 to 5%) frequency in whole (cancer)
genome sequencing studies [154].
Generally, a large number of mutations occur in can-
cer genomes, such as somatic mutations, CNAs, methy-
lation aberrations and histone modifications. It is critical
to distinguish driver mutations and driver genes (which
contribute to the progression of cancer from normal to
malignant states) from passenger mutations and passen-
ger genes (which accumulate in cells but do not contrib-
ute to cancer development). There is a subtle difference
between a driver gene and a driver gene mutation. A
driver gene harbours driver gene mutations but may also
harbour passenger gene mutations. A driver mutation
typically confers upon a tumour only a very small
growth advantage, which may be as low as a 0.4% in-
crease in the difference between cell birth and death
rates [155]. More recently, Bozic and colleagues have
shown that the first, and hence most abundant, passen-
ger mutations are influenced both by the mutation rate
and by the death-birth ratio of the cancer cells [156]. It
should be appreciated that whilst passenger mutations
do not, by definition, exert a strong selective growth ad-
vantage, they are not entirely neutral. Indeed, many are
deleterious in terms of their effect on cellular
proliferation and cancer progression [157, 158]. It should
also be appreciated that whilst the damaging effect of a
non-synonymous passenger mutation is on average 100
times smaller than the effect of a driver mutation, pas-
sengers are 100 times more numerous than drivers
[158]. The paucity of drivers in a sea of passenger muta-
tions represents a challenge to identifying the former.
This task is made all the more daunting by the possibil-
ity that drivers and passengers are not discrete entities
but rather lie along a continuum which includes latent
driver mutations which ‘behave as passengers but
coupled with other emerging mutations, drive cancer de-
velopment and drug resistance’ [159].
In 2004, Futreal and colleagues published a ‘Census of
human cancer genes’ which aimed to list all genes that
are causally implicated in tumorigenesis. This census has
been kept up to date and currently includes 602 entries
[43, 160]. This implies that more than 2% of all human
genes are implicated in cancer. Of these, approximately
90% have somatic mutations in cancer; 20% have germ-
line mutations that predispose to cancer; and 10%
harbour both somatic and germline mutations. A second
resource, the Network of Cancer Genes (NCG) contains
a total of 1053 ‘cancer genes’ whose possible involve-
ment in cancer has been inferred by statistical means
[161]. The number of genes recognized as being cancer-
associated is likely to increase as new techniques are de-
vised to identify the function of the associated proteins
[162, 163].
Cooperativity and exclusivity of NF1 somatic mutations
Mitogen-activated protein kinases (MAPK) and
phosphoinositide-3 kinase (PI3K) pathways are key cellular
growth regulators. In a normal cell, these control cell
growth and survival but are often disrupted in a malignant
cell with a deregulated MAPK or PI3K pathway. It is now
well recognized that the focus should be upon cellular path-
ways rather than on individual genes to achieve a full un-
derstanding of cancer biology. Therefore, defining driver
pathways is an important step to understanding the mo-
lecular mechanisms underlying cancer. Previous studies
have focussed mainly on identifying the alterations in can-
cer genomes at the individual gene or single pathway level.
However, a great deal of evidence indicates that multiple
pathways often function cooperatively in carcinogenesis
and other key biological processes. A common and re-
stricted number of driver genes and pathways are probably
responsible for most common forms of cancer [40, 147].
In general, mutations of the genes in one pathway usu-
ally exhibit mutual exclusivity, because a single mutation
is usually enough to disturb one pathway and any fur-
ther hits in other components of that pathway confer no
added selectable advantage. Thus, sporadic tumours with
NF1 mutations are mutually exclusive for mutations in
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MAPK kinase 1 (MAP2K1) or NRAS. Strongly activating
‘canonical’ mutations in oncogenes (for example G12D or
G12V mutations in KRAS) can drive cancer formation on
their own and are known to be epistatic in relation to
other canonical mutations within the same pathway [164].
However, whether there are, for example, ‘non-canonical’
mutations that weakly activate oncogenes or only partially
inactivate tumour suppressor activity and yet can drive
cancer formation is less clear. Examination of genomic
data from the Cancer Cell Line Encyclopedia (CCLE) and
TCGA has indicated that whilst canonical KRAS muta-
tions do not occur with increased frequency in the context
of NF1 mutations, non-canonical KRAS mutations cer-
tainly do, suggesting that such pairs of mutations might
act together to confer a selective advantage in human tu-
mours [164]. Activation of RAS guanine nucleotide ex-
change factors (RAS-GEFs) was predicted to have similar
effects to neurofibromin loss and that non-canonical
KRAS mutations co-occur with RAS-GEF mutations in
TCGA and CCLE data [164]. Furthermore, increased fre-
quencies of mutations in both NF1 and other RAS path-
way activators or effectors have been found which
suggests that this principle could apply more broadly to
other genes in the RAS network and possibly to other
oncogenic signalling pathways [58]. Subsequently, NF1
loss has been described as a key mediator of acquired and
intrinsic BRAF inhibitor resistance following a high-
throughput short hairpin RNA screening approach [53].
Furthermore, on the basis of analyses of somatic co-
mutation patterns in the TCGA data sets (cBio Portal for
Cancer Genomics), 9.6% of melanomas with NF1 muta-
tions also have mutations in BRAF, NRAS or RAF1 [47].
But, whilst mutant NF1 is known to cooperate with RASo-
pathy genes (RASA2, PTPN11, SOS1, RAF1 and SPRED1)
in melanoma and although NF1 is found to be frequently
mutated (25–30%) in melanomas harbouring wild-type
BRAF and NRAS, it is curious that melanoma is not a
tumour type associated with NF1 [8, 49–51].
The capacity of NF1 mutations to act both coopera-
tively and exclusively without BRAF and NRAS muta-
tions in melanoma may be mediated through pathways
other than the MAPK pathway. Maertens and colleagues
have identified increased activation of the PI3K/AKT/
mTOR pathway in BRAF/NF1 double mutants, and a
combinatorial MEK marker and mTOR inhibitor treat-
ment has proven effective in many MEK inhibitor-
resistant neoplasms [58]. In a glioblastoma animal model,
NF1 cooperates with both TP53 and PTEN, but no co-
occurrence of NF1 and BRAF mutations is seen [137].
Moreover, whilst simultaneous inactivation of Nf1 and
expression of K-RasG12D in mouse haematopoietic cells
results in AML that was fatal in primary mice within
4 weeks, in ovarian serous carcinomas, cooperation be-
tween mutant TP53 and NF1 results in a poor prognosis
[92, 117]. In addition, an association between inactivated
NF1 and ZNF423 levels in neuroblastomas has been iden-
tified as a putative prognostic marker [130].
It should be appreciated that the same gene can func-
tion in completely opposite ways in different cell types. In
melanomas harbouring BRAF V600E mutations, a BRAF
inhibitor induces remission of the tumour; however, the
same drug is ineffective in colorectal cancer cells harbour-
ing identical mutations. This has been attributed to the
expression of EGFR which occurs in some colorectal can-
cers, but not in melanomas [165].
Despite all the cancer genome information available
regarding NF1, it remains unclear why NF1 patients are
predisposed only to certain types of tumours. Why, for
example, are NF1 patients not predisposed to lung tu-
mours given that at least 10% of all sporadic lung can-
cers have NF1 mutations [8, 65, 72, 166]?
NF1 and drug resistance
The RAS/MAPK pathway, with an important role in can-
cer biology, is a prime target for anti-cancer agents; how-
ever, the presence of an NF1 mutation, resulting in
reduced expression of neurofibromin, confers resistance
to several therapeutic drugs. Furthermore, NF1-associated
drug resistance to RAF and EGFR inhibitors, tamoxifen
and retinoic acid, has been observed in melanoma, lung
cancers, breast cancers and neuroblastoma, respectively,
and melanoma cells with BRAF/NF1 mutations develop
resistance to BRAF inhibitors [58, 111, 130, 167]. It is not
clear whether the specific nature of the mutations could
have exerted an influence on the sensitivity of the drug, as
complete inactivation of NF1 has been noted to confer
sensitivity to rapamycin in AML [85].
Mutational spectrum
Large constitutional NF1 deletions, encompassing the
NF1 gene and many adjacent genes, occur in 5–10% of
NF1 cases and are often associated with a more severe
phenotype including learning disabilities and increased
susceptibility to MPNSTs [168, 169]. Intriguingly, such
mutations resulting in heterozygous or homozygous loss
of NF1 expression are found to occur more often as
sporadic events in AML and ovarian carcinoma, based
on cBioPortal data [45]. An NF1 microdeletion in com-
bination with an abnormal karyotype is an indicator of
poor prognosis in AML; 7.6% of ovarian serous cystadeno-
carcinomas, 2.8% of lung squamous cell carcinomas, 3.3%
of glioblastomas and 1.9% of phaeochromocytomas/para-
gangliomas harboured deletions [45, 82, 84].
NF1 amplification, and presumably increased neurofi-
bromin expression and hence activity, has been identi-
fied in many cancers, including breast (17%), pancreatic
(21.5%), uterine endometrial (1.8%) and neuroendocrine
prostate cancer (21.5%) [45].
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The pathological significance of sporadic NF1 point
mutations, especially putative missense mutations that
have been identified in many sporadic tumours, is
often unclear. Constitutional NF1 missense mutations
represent about 15% of all NF1 mutations, but their
frequency in sporadic tumours ranges widely from 15
to 71% [24, 25, 45, 72, 106, 143, 167, 170–172]. The
characterization of such missense mutations has
yielded new insights into the structure and function
of neurofibromin. For example, through analysis of
missense mutations, the arginine finger loop of the
neurofibromin GRD has been found to be crucial for
stabilizing the transition state of the GTPase reaction,
and many missense mutations in the GRD have been
found to exert a significant, pathological effect on Ras
activity levels [36, 173, 174].
Conclusion
Somatic NF1 mutations are present in tumours asso-
ciated with NF1 and in a range of sporadic tumours,
in different cell types and at various frequencies
(Table 1). The frequency and temporal occurrence of
somatic mutations and the range of histological
types in which they occur therefore imply an import-
ant role for neurofibromin function in cancer devel-
opment and progression. Whilst it is unclear
whether the biallelic loss of NF1 is common or if
only heterozygous mutations of NF1 contribute to
tumour progression in sporadic tumours, mouse cells
heterozygous for Nf1 mutations show abnormal
growth and invasion [138, 175].
Somatic NF1 mutations may be critical drivers in mul-
tiple cancers as well as contributing to resistance to
therapy. The mutational landscape of somatic NF1 mu-
tation should provide new insights into our understand-
ing of the pathophysiology of cancer.
The introduction of a molecular genomics approach
to cancer biology represents a major shift in our ap-
proach to the diagnosis and treatment of malignancy.
The vast amount of genomic data generated over the
last 10 years, which continues to be generated, is pro-
viding invaluable insights into the complexities of
cancer genome structure, function and evolution.
With recent advances in sequencing technology and
high-throughput drug discovery, the increasing avail-
ability of more sophisticated animal models and the
application of the state-of-the-art tumour imaging
techniques and the diagnosis and treatment of cancer
can only improve. The identification of somatic NF1
mutations in such a wide spectrum of tumours, in-
cluding types not associated with NF1, indicates that
neurofibromin is likely to play a key role in cancer,
far beyond that evident in the tumour predisposition
syndrome NF1.
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